NSRX (Nasus Pharma) Ending Cash Position: $7.90 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSRX Nasus Pharma Ltd NSRX
14 GF Score
Price $4.08
! 4 Warning Signs
View Full Analysis

What is Nasus Pharma Ending Cash Position?

Nasus Pharma NSRX +0.25% 14 Ending Cash Position is $7.90 Mil as of Jun. 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review.

Nasus Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 was $7.90 Mil.

Nasus Pharma's quarterly Ending Cash Position increased from Jun. 2025 ($0.23 Mil) to Dec. 2025 ($1.29 Mil) and increased from Dec. 2025 ($1.29 Mil) to Jun. 2026 ($7.90 Mil).

Nasus Pharma's annual Ending Cash Position increased from Dec. 2023 ($0.21 Mil) to Dec. 2024 ($0.31 Mil) and increased from Dec. 2024 ($0.31 Mil) to Dec. 2025 ($1.29 Mil).

Nasus Pharma Ending Cash Position Related Terms

Nasus Pharma Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Nasus Pharma's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nasus Pharma Ending Cash Position Chart

Nasus Pharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Ending Cash Position
0.17 0.21 0.31 1.29

Nasus Pharma Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Ending Cash Position Get a 7-Day Free Trial 0.92 0.31 0.23 1.29 7.90
NSRX
14GF Score
Nasus Pharma Ltd NSRX
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nasus Pharma Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Nasus Pharma's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=0.311+0.98
=1.29

Nasus Pharma's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1.291+6.613
=7.90

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $7.90 Mil mean?
Nasus Pharma (NSRX) has a Ending Cash Position of $7.90 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nasus Pharma and its competitors.
Is Nasus Pharma's Ending Cash Position too high?
Nasus Pharma's current Ending Cash Position is $7.90 Mil. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's Ending Cash Position compare to MIRA and SCLX?
Nasus Pharma's Ending Cash Position of $7.90 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Nasus Pharma and its competitors. Nasus Pharma's current Ending Cash Position is $7.90 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current Ending Cash Position of $7.90 Mil. The current Ending Cash Position is $7.90 Mil. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current Ending Cash Position is $7.90 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nasus Pharma Business Description

Address Yigal Alon 65, Tel Aviv, ISR, 6744317
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score

Get the complete analysis for NSRX

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.08
Price